Precipio, Inc. PRPO
We are a healthcare biotechnology company with a mission to battle the systemic problem of disease misdiagnosis, by focusing on improving cancer diagnostics, particularly, hematologic malignancies. Our objective is to enhance diagnostic accuracy and accessibility while building a sustainable business model that supports ongoing innovation. We aim to achieve this through a combination of clinical laboratory services and proprietary diagnostic product development. By integrating diagnostic services with product development, our service business doubles as a self-funded research and development ("R&D") unit, enabling us to achieve rapid and cost-efficient innovation rather than being a major cost center for us.
Valuation FY2025 figures against the last close
Annual financial statements
Income statement
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $24.2M | $18.6M | $15.4M | $9.8M | $8.7M | $7.4M | $4.1M | $3.4M | $2.0M | $1.7M |
| Cost of revenue | $13.3M | $11.0M | $9.2M | $6.9M | $6.5M | $4.9M | $2.9M | $2.6M | $1.4M | $970.0K |
| Gross profit | $10.7M | $7.6M | $6.0M | $2.5M | $2.4M | $1.1M | $219.0K | $225.0K | $292.0K | $753.0K |
| R&D | $1.6M | $1.3M | $1.7M | $1.7M | $1.3M | $1.2M | $1.2M | $1.1M | $500.0K | $0 |
| SG&A | — | — | — | — | — | $10.3M | $9.6M | $9.5M | $6.5M | $2.5M |
| Total operating expenses | $11.9M | $11.8M | $13.6M | $15.3M | $12.0M | $10.3M | $11.2M | $14.1M | $15.8M | $2.5M |
| Operating income | -$1.2M | -$4.2M | -$7.6M | -$12.8M | -$9.6M | -$9.1M | -$11.0M | -$13.9M | -$15.5M | -$1.7M |
| Pre-tax income | -$363.0K | -$4.3M | -$5.9M | -$12.2M | -$8.5M | -$10.6M | -$13.3M | -$16.0M | -$20.7M | -$2.2M |
| Income tax | $0 | $0 | $0 | $0 | $0 | $0 | $70.0K | $279.0K | $349.0K | $0 |
| Net income | -$363.0K | -$4.3M | -$5.9M | -$12.2M | -$8.5M | -$10.6M | -$13.2M | -$15.7M | -$20.7M | -$2.2M |
| EPS, basic | -0.23 | -2.93 | -4.51 | -10.73 | -0.40 | -0.85 | — | — | — | — |
| EPS, diluted | -0.23 | -2.93 | -4.51 | -10.73 | -0.40 | -0.85 | -2.33 | -13.82 | -7.16 | -9.44 |
| Shares, diluted (wtd. avg.) | $1.6M | $1.5M | $1.3M | $1.1M | $21.1M | $16.5M | — | — | — | — |
Balance sheet
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | $2.7M | $1.4M | $1.5M | $3.4M | $11.7M | $2.7M | $848.0K | $381.0K | $421.0K | $51.0K |
| Receivables | $2.0M | $799.0K | $1.3M | $1.0M | $697.0K | $874.0K | $574.0K | $690.0K | $730.0K | $388.0K |
| Inventory | $935.0K | $724.0K | $384.0K | $708.0K | $564.0K | $350.0K | $184.0K | $197.0K | $161.0K | $100.0K |
| Total current assets | $6.0M | $3.5M | $3.7M | $5.7M | $13.5M | $4.2M | $1.9M | $1.8M | $1.7M | $552.0K |
| Property, plant and equipment | $729.0K | $719.0K | $739.0K | $877.0K | $836.0K | $277.0K | $431.0K | $496.0K | $353.0K | $280.0K |
| Goodwill | — | — | — | — | — | — | — | — | $4.7M | — |
| Other intangibles | $10.9M | $11.9M | $12.8M | $13.8M | $14.7M | $15.7M | $16.7M | $19.3M | $20.5M | $562.0K |
| Total assets | $21.3M | $17.0M | $18.1M | $21.5M | $30.4M | $20.7M | $19.5M | $21.6M | $27.3M | $842.0K |
| Accounts payable | $1.1M | $618.0K | $622.0K | $2.0M | $1.9M | $1.7M | $1.9M | $5.2M | $5.1M | $1.1M |
| Short-term debt | $30.0K | $297.0K | $235.0K | $255.0K | $26.0K | $648.0K | $321.0K | $263.0K | $587.0K | $395.0K |
| Total current liabilities | $3.8M | $4.3M | $3.1M | $4.4M | $4.2M | $4.7M | $4.3M | $13.8M | $10.0M | $3.0M |
| Long-term debt | $47.0K | $77.0K | $106.0K | $134.0K | $160.0K | $362.0K | $198.0K | $253.0K | $2.8M | $4.1M |
| Total liabilities | $6.8M | $4.9M | $3.7M | $5.1M | $5.8M | $6.6M | $6.3M | $15.5M | $14.2M | $7.3M |
| Retained earnings | -$102.8M | -$102.4M | -$98.2M | -$92.3M | -$80.1M | -$71.6M | -$60.9M | -$47.7M | -$31.5M | -$10.8M |
| Total equity | $14.6M | $12.1M | $14.4M | $16.4M | $24.6M | $14.2M | $13.2M | $6.1M | $13.0M | -$6.5M |
Cash flow
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | $685.0K | $439.0K | -$3.6M | -$7.7M | -$6.6M | -$7.4M | -$9.1M | -$6.8M | -$6.7M | -$959.0K |
| Depreciation and amortisation | $1.2M | $1.2M | $1.2M | $1.2M | $1.1M | $1.1M | $1.1M | $1.3M | $743.0K | $112.0K |
| Stock-based compensation | $1.2M | $1.5M | $1.6M | $3.8M | $1.9M | $703.0K | $668.0K | $529.0K | $49.0K | $12.0K |
| Capital expenditure | $326.0K | $223.0K | $126.0K | $277.0K | $682.0K | $151.0K | $55.0K | $97.0K | $143.0K | $19.0K |
| Investing cash flow | -$326.0K | -$223.0K | -$126.0K | -$277.0K | -$682.0K | -$96.0K | -$55.0K | -$97.0K | -$42.0K | $1.0M |
| Financing cash flow | $903.0K | -$329.0K | $1.7M | -$225.0K | $16.3M | $9.3M | $9.7M | $6.8M | $7.1M | $775.0K |
Figures as tagged in each year's own filing, in US dollars. A year restated by a later filing shows the restated figure. Capital expenditure, dividends and buybacks are cash out, shown positive. A line the filer does not report is not listed. Latest from accession 0001140361-26-017462.
Others in SIC 3826
| Ticker | Company | Market cap | P/E | Revenue growth |
|---|---|---|---|---|
| A | AGILENT TECHNOLOGIES, INC. | $42.53B | 33.0x | 6.7% |
| WAT | WATERS CORP /DE/ | $40.22B | 38.0x | 7.0% |
| ILMN | ILLUMINA, INC. | $32.95B | 40.0x | -0.7% |
| MTD | METTLER TOLEDO INTERNATIONAL INC/ | $26.95B | 32.0x | 4.0% |
| RVTY | REVVITY, INC. | $14.53B | 62.9x | 3.7% |
| BIO | BIO-RAD LABORATORIES, INC. | $10.33B | 13.9x | 0.7% |
| AVTR | Avantor, Inc. | $10.22B | — | -3.4% |
| BRKR | BRUKER CORP | $8.88B | — | 2.1% |